Completed
Nutritional intervention for non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD) in HIV: The role of nutritional interventions
Learn MoreCompleted
Non-alcoholic fatty liver disease (NAFLD) in HIV: The role of nutritional interventions
Learn MoreCompleted
A pilot, prospective, open-label study to evaluate the safety and efficacy of Kaletra® monotherapy in HIV/HCV co-infected subjects
Learn MoreCompleted
Predicting Abnormalities in Lactate Production and Clearance Related to Treatment and Liver Disease and Measuring the Impact of Vitamin Supplementation
Learn MoreCompleted
Vicriviroc in combination treatment with an optimized ART regimen in HIV-infected treatment-experienced subjects
Learn MoreCompleted
A Multicenter, randomized, double-blind, double-dummy, phase 3 study of the safety and efficacy of Ritonavir-boosted Elvitegravir (EVG/r) versus Raltegravir (RAL)
Learn MoreCompleted
A randomised, double blind, double dummy, parallel group, active controlled trial to evaluate the antiviral efficacy of 400 mg QD neVirapine Extended Release formulation in comparison to 200 mg BID neVirapinE immediate release in combination with Truvada™ in antiretroviral therapy naïve HIV-1 infected patients. (VERxVE study)(Trial number 1100.1486)
Learn MoreCompleted
48-Week Study of GW433908 and Ritonavir or GW433908 Alone, Twice Daily in Pediatric Patients with HIV Infection.
Learn MoreCompleted
CTN Trials have been approved by the Community Advisory Committee of the Canadian HIV Trials Network and the Network’s Scientific Review Committee, or other national peer-review panels such as those at the Canadian Institutes of Health Research and the U.S. National Institutes of Health. CTNPT studies are small-scale investigations designed to determine the feasibility of research concepts, and do not all go through the regular CTN clinical trial review process. For information on the benefits and risks of participating in HIV clinical trials, call CATIE toll-free at 1-800-263-1638.